Statins in sepsis

Journal of Pharmacy Practice

Volumn 23, Issue 1, 2010, Pages 38-49

  Dobesh, Paul P ^a   Swahn, Stephanie M ^a   Peterson, Evan J ^a   Olsen, Keith M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Critical care; Inflammation; Pneumonia; Sepsis; Statins

Indexed keywords

ACTIVATED PROTEIN C; ENDOTOXIN ANTIBODY; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TUMOR NECROSIS FACTOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APACHE; ARTIFICIAL VENTILATION; ATHEROSCLEROSIS; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG MEGADOSE; DYSLIPIDEMIA; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; INTENSIVE CARE UNIT; MORTALITY; PATHOPHYSIOLOGY; PLEIOTROPY; PNEUMONIA; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 77949385932     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009356548     Document Type: Review

References (76)

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-1554.
2. Angus DC, Linde-Zwirble WT, Lidicker A, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7): 1303-1310.
3. Dombrovskiy VY, Martin AA, Sunderran J, et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 300. Crit Care Med. 2007;35(5):1244-1250.
4. Esper A, Martin GS. Is severe sepsis increasing in incidence AND severity? Crit Care Med. 2007;35(5):1414-1415.
5. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hours in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003;31(9): 2332-2338.
6. Vincent JL, Sakr Y, Sprung CL, et al., for the Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-353.
7. Dombrovskiy VY, Martin AA, Sunderram J, et al. Facing the challenge: decreasing case fatality rates in severe sepsis despite increasing hospitalizations. Crit Care Med. 2005;33(11): 2555-2562.
8. Kochanek KD, Murphy SL, Anderson RN, et al. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53(5):1-115.
9. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250- 1256.
10. American College of Chest Physicians/Society of Critical Care Medicine. American College of Chest Physicians/Society of Critical Care Medicine consensus conference; definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.
11. Rivers E, Nguyen B, Havstad S. et al., for the Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
12. Houck PM,MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119(5): 1420-1426.
13. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the surgical intensive care unit. N Engl J Med. 2001;345(19):1359-1367.
14. Remick DG. Pathophysiology of sepsis. AJP. 2007;170(5): 1435-1444.
15. Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Critical Care. 2006;10(1):113-115.
16. Kim YS, Ahn Y, Hong MH, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-kappaB in endothelial cells. J Cardiovasc Pharmacol. 2007;49(6):376-383.
17. Rasmussen LM, Hansen PR, Nabipour MT, et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J. 2001;360(pt 2):363-370.
18. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30(5):1212-1217.
19. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis. 2003;14(6):575-585.
20. Huang KC, Chen CW, Chen JC, et al. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci. 2003;10(4):396-405.
21. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147(2):253-261
22. Diomede L, Albani D, Sottocorno M, et al. In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21(8):1327-1332.
23. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 1996;125(8):680-687.
24. Ando H, Takamura T, Ota T, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther. 2000;294(3):1043-1046.
25. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353(9157): 983-984.
26. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation. 2004;110(21):3349- 3354.
27. Chen CH, Lee RP, Wu WT, et al. Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation. 2007;74(1):166-174.
28. Buerke U, Carter JM, Schlitt A, et al. Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock. 2008;29(4):497-503.
29. Inoue I, Goto S,Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67(8):863-876.
30. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101(15):1760-1763.
31. Lin R, Liu J, Peng N, et al. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull. 2005;28(9):1630-1634.
32. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(1):58-63.
33. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
34. van der Harst P, Asselbergs FW, Hillege HL, et al. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. Am J Cardiol. 2007;100(10):1548-1551.
35. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation. 2005;111(14):1841-1846.
36. Paumelle R, Blanquart C, Briand O, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98(3):361-369.
37. Ghittoni R, Napolitani G, Benati D, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol. 2006;36(11):2885-2893.
38. Kwak B, Mulhaupt F, Veillard N, et al. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly. 2001;131(3-4):41-46
39. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001;133(3):406-412.
40. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7(6):687-692.
41. Li X, Klintman D, Weitz-Schmidt G, et al. Lymphocyte function antigen-1 mediates leukocyte adhesion and subsequent liver damage in endotoxemic mice. Br J Pharmacol. 2004;141(4):709-716.
42. Duplessis CA, Fothergill D. Investigating the potential of statin medications as a nitric oxide (NO) release agent to decrease decompression sickness: a review article. Med Hypotheses. 2008;70(3):560-566.
43. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest. 2003;124(2):740-743.
44. Alvarez de Sotomayor M, Vega S, Mingorance C, et al. Effects of HMG-CoA reductase inhibition by simvastatin on vascular dysfunction induced by lipopolysaccharide in rats. Pharmacology. 2008;82(2):89-96.
45. Sharshar T, Gray F, Lorin de la Grandmaison G, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet. 2003;362(9398):1799-1805.
46. Terblanche M, Almog Y, Rosenson RS, et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007;7(5):358-368.
47. Durant R, Klouche K, Delbosc S, et al. Superoxide anion overproduction in sepsis: effects of vitamin e and simvastatin. Shock. 2004;22(1):34-39.
48. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37(12):2064-2071.
49. Hong H, Zeng JS, Kreulen DL, et al. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol. 2006;291(5):H2210-H2215.
50. Jacobson JR, Dudek SM, Birukov KG, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004;30(5):662-670.
51. Esmon C. The protein C pathway. Crit Care Med. 2000;28(suppl 1):S44-S48.
52. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851-1861.
53. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20(2):556-562.
54. Swiatkowska M, Pawlowska Z, Szemraj J, et al. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by downregulation of cellular signaling and the inhibition of PAI-1 promoter activity. Jpn J Pharmacol. 2002;90(4):337-344.
55. Wiesbauer F, Kaun C, Zorn G, et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol. 2002;135(1):284-292.
56. Kunieda Y, Nakagawa K, Nishimura H, et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res. 2003;110(4): 227-234.
57. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103(2):276-283.
58. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev. 2001;184:258-274.
59. Hölschermann H, Hilgendorff A, Kemkes-Matthes B, et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000;69(9):1830-1836.
60. Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 1999;33(5):1286-1293.
61. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001;33(8):1352-1357.
62. Almong Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110(7):880-885.
63. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6: 82-88.
64. Kruger P, Fitzsimmons K, Cook D, et al. Statin therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med. 2006;32(1):75-79.
65. Schmidt H, Hennen R, Keller A, et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med. 2006;32(8): 1248-1251.
66. Dobesh PP, Klepser DG, McGuire TR, et al. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy. 2009;29(6):621-630.
67. Martin CP, Talbert RL, Burgess DS, et al. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy. 2007;27(1):20-26.
68. Yang KC, Chien JY, Tseng WK, et al. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med. 2007;25(5):494-501.
69. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med. 2006;32(1):160-164.
70. Hackam DG, Mamdani M, Li P, et al. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367(9508):413-418.
71. Thomsen RW, Riis A, Kornum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008;168(19):2081-2087.
72. Almong Y, Novack V, Eisinger M, et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med. 2007;35(2):372-378.
73. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999.
74. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007;27(3):325-332.
75. Van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. ThorX. 2006;61(11):957-961.
76. Gupta R, Plantinga LC, Fink NE, et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA. 2007;297(13):1455-1464.